* u.s. Fda grants fast track designation for her2-targeting
antibody drug conjugate ds-8201 for her2-positive metastatic
breast cancer
The post BRIEF-U.S. FDA grants designation for HER2-targeting antibody drug conjugate DS-8201 appeared first on NASDAQ.